U.S. Pharmacopeia
The Standard of Quality℠

Headquarters
12601 Twinbrook Parkway
Rockville, Maryland 20852
+1-301-881-0666

Europe/Middle East/Africa
Münchensteinerstrasse 41
CH-4052 Basel, Switzerland
+41 (0)61 316 30 10

USP–India Private Limited
IKP Knowledge Park
Turkapally Village
Genome Valley
Shameerpet, Ranga Reddy District
Hyderabad 500 078, A.P., India
+91-40-2348-0088

USP–China
Building 11, Lane 67 Libing Road,
Zhangjiang Hi-Tech Park
201203 Shanghai
China
+86-21-51370600

USP–Brazil
Avenida Ceci, 1600 - Tamboré
Barueri-SP
06460-120
Brazil
+ 55 -11-3245-6400

www.usp.org

Veterinary Drugs Stakeholder Forum
Meeting #1 for 2010-2015
Friday, November 9, 2012
USP Headquarters, Rockville, Maryland
Sanja Modric, DVM, Ph.D., FDA Center for Veterinary Medicine (CVM), Chair

Draft Agenda

Goals and Expected Outcomes

1. Provide updates on topics of interest
2. Receive stakeholder feedback

7:30 a.m.	**Registration, Continental Breakfast**	
8:30 a.m.	**1. Opening, Welcome, and Call to Order**	Mario Sindaco, Sanja Modric
8:40 a.m	**2. Overviews**	
	a. CVM and American Academy of Veterinary Pharmacology and Therapeutics (AAVPT) Overview	Sanja Modric
9:00 a.m.	b. American Veterinary Medical Association (AVMA) Overview	Lynne White-Shim
9:15 a.m.	c. Industry Overview Animal Health Institute (AHI)	Grace Gowda
9:30 a.m.	d. Industry Overview Generic Animal Drug Alliance (GADA)	TBD
9:45 a.m.	e. USP Overview	Karen Russo
10:00 a.m.	**3. Next Steps of the Veterinary Solubility Criteria Workshop**	Marilyn Martinez/USP staff
10:10 a.m.	Break	
10:30 a.m.	**4. USP General Chapters and their Impact on Industry**	
	a. Industry Perspective	Roger Butler and TBA
	b. Regulatory Perspective	Laura Huffman
	c. USP Perspective	Anthony DeStefano
	d. Discussion	
12:00 p.m.	Lunch	
1:00 p.m.	**5. Unapproved Veterinary Drugs: Background and Possible Roles for USP**	
	a. Regulatory Perspective	Janice Steinschneider
	b. GADA Perspective	TBD
	c. AHI Perspective	Jennifer Harmer
	d. AVMA Perspective	Lynne White-Shim
	e. Discussion	
2:15 p.m.	Break	
2:30 p.m.	**6. Compounding: Background and USP's Role**	
	a. Regulatory Perspective	Janice Steinschneider
	b. AVMA Perspective	Butch KuKanich
	c. Industry Perspective	Rob Hunter
	d. USP Perspective	Gigi Davidson
	e. Discussion	
4:00 p.m.	**7. Stakeholder Forum Summary and Next Steps**	
4:15 p.m.	**Adjourn**	